Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.

Abstract

We aimed to investigate whether the PTPRC rs10919563 A/G and Fc gamma receptor 2A (FCGR2A) R131H polymorphisms can predict the response to anti-TNF therapy in rheumatoid arthritis (RA) patients. We conducted a meta-analysis of studies on the association between the PTPRC rs10919563 A/G or the FCGR2A R131H polymorphism and responsiveness to anti-TNF therapy in RA patients. Eighteen studies (twelve on PTPRC and six on FCGR2A) from eight articles involving 3058 patients were considered in this meta-analysis. The meta-analysis showed a significant association between the PTPRC rs10919563 A allele and response to TNF-α blockers in RA. The OR of the PTPRC A allele was significantly lower in responders (OR=0.584, 95% CI=0.409-0.835, P=0.003). Meta-analysis revealed no association between the FCGR2A HH+HR genotype and responsiveness to TNF blockers in all study subjects (OR=0.762, 95% CI=0.543-1.068, P=0.115). However, stratification by TNF inhibitor type showed that the FCGR2A HH+HR genotype was associated with responsiveness to adalimumab (OR=0.591, 95% CI=0.369-0.947, P=0.029), but not infliximab and etanercept (OR=0.929, 95% CI=0.354-2.440, P=0.881; OR=0.804, 95% CI=0.293-2.207, P=0.673). The PTPRC rs10919563 A allele shows a poor response to anti-TNF therapy, and the FCGR2A HH+HR genotype shows a poor response to adalimumab for RA. Genotyping for these polymorphisms may be useful for predicting the response to TNF-α blockers with respect to personalized medicine.